Drugs That Distort Aldosterone Testing: What to Stop and When

Why Drug Interference Matters for Aldosterone Testing

An accurate aldosterone-to-renin ratio is the gatekeeper for diagnosing primary aldosteronism (PA), a condition present in 5 to 13% of hypertensive patients. Miss PA and you miss a surgically curable cause of high blood pressure. Drug interference is the most common reason screening fails.

The 2016 Endocrine Society Clinical Practice Guideline states plainly: "Medications that markedly affect the ARR should be withdrawn for an appropriate period before ARR determination" [1]. That "appropriate period" varies from two to six weeks depending on the drug class. The problem is practical. Many patients take three or four interfering medications simultaneously, and clinicians are often reluctant to pause them. A 2020 retrospective at Mayo Clinic found that 43% of initial ARR screens were performed while patients were still taking at least one interfering agent [2]. Nearly one in five of those tests had to be repeated. The time, cost, and diagnostic delay add up quickly.

Understanding exactly which drugs push aldosterone up, which suppress it, which distort renin, and which do both is not optional knowledge for anyone ordering or interpreting this test.

Mineralocorticoid Receptor Antagonists: The Biggest Offenders

Spironolactone and eplerenone directly block the mineralocorticoid receptor, triggering a compensatory rise in both aldosterone and renin. The effect on aldosterone can persist for four to six weeks after discontinuation because spironolactone's active metabolite, canrenone, has a half-life exceeding 16 hours and accumulates in tissue [3].

The Endocrine Society mandates a minimum four-week washout for MRAs before ARR testing [1]. Some experts extend this to six weeks for patients on high-dose spironolactone (above 100 mg daily). Eplerenone clears faster, with a plasma half-life of roughly 4 to 6 hours, but the guideline applies the same four-week minimum to both agents.

During the washout window, blood pressure often rebounds. The guideline recommends substituting verapamil sustained-release (120 to 240 mg daily) as first-line, with hydralazine or doxazosin added if needed [1]. These agents have minimal effect on the ARR.

A practical point: amiloride, while not an MRA, also blocks epithelial sodium channels influenced by aldosterone. It raises plasma aldosterone modestly and should be stopped at least four weeks before screening [4].

ACE Inhibitors and ARBs: False Negatives Waiting to Happen

Angiotensin-converting enzyme inhibitors (lisinopril, enalapril, ramipril) and angiotensin receptor blockers (losartan, valsartan, telmisartan) lower aldosterone production while simultaneously raising plasma renin activity. The net result is a suppressed ARR that can mask PA entirely.

In a study of 118 patients with confirmed PA, losartan reduced the ARR below the diagnostic threshold in 34% of cases when the drug was not discontinued before testing [5]. Renin rose by an average of 2.8-fold, while aldosterone dropped by roughly 25%. The combination flattened the ratio in patients who clearly had autonomous aldosterone production.

The recommended washout is at least two weeks for both ACE inhibitors and ARBs [1]. Dr. William Young Jr. of Mayo Clinic has noted: "If you screen patients on an ACE inhibitor and the ARR is elevated, the result is likely a true positive. But a normal ARR on these drugs cannot rule out primary aldosteronism" [6]. This asymmetry is clinically important. A positive result on an ACE inhibitor is meaningful. A negative one is not.

For patients whose blood pressure is controlled only by an ACE inhibitor or ARB, switching to verapamil SR plus hydralazine for two weeks is the standard approach. Prazosin (1 to 5 mg twice daily) can be added for additional control [1].

Beta-Blockers: Renin Suppression Creates False Positives

Beta-adrenergic blockers (propranolol, atenolol, metoprolol, carvedilol) suppress renin secretion from the juxtaglomerular cells. With renin driven down, the ARR rises even when aldosterone itself is normal or low. The result is a false-positive screen.

A prospective study in the Journal of Hypertension showed that propranolol increased the ARR above 30 in 26% of essential hypertension patients who did not have PA [7]. The false-positive rate was highest with non-selective beta-blockers but still reached 14% with atenolol.

The Endocrine Society recommends a two-week washout for beta-blockers [1]. This timeline deserves caution. Abrupt withdrawal of beta-blockers can provoke rebound tachycardia, angina in patients with coronary artery disease, or hypertensive urgency. Tapering over 7 to 10 days before a full two-week washout is safer.

Central alpha-2 agonists like clonidine and methyldopa also suppress renin. Clonidine has the added problem of raising aldosterone slightly. Methyldopa interferes with some aldosterone assays at the chemical level, producing spurious elevations on older radioimmunoassay platforms [1]. Both require a two-week washout.

Diuretics: Volume Depletion Confounds Everything

Thiazide diuretics (hydrochlorothiazide, chlorthalidone) and loop diuretics (furosemide, bumetanide, torsemide) cause sodium and volume depletion that activates the renin-angiotensin-aldosterone system. Both renin and aldosterone rise. The effect on the ARR is variable but trends toward false negatives because renin typically rises proportionally more than aldosterone [8].

There is a second mechanism. Diuretic-induced hypokalemia independently suppresses aldosterone secretion from the adrenal zona glomerulosa. A patient who is hypokalemic at the time of screening may show a normal aldosterone level despite having an aldosterone-producing adenoma. The Endocrine Society specifically warns: "Hypokalemia should be corrected before ARR testing, as it directly suppresses aldosterone secretion" [1].

The washout period for diuretics is four weeks, matching MRAs [1]. Potassium should be repleted to at least 4.0 mEq/L before the test. Patients on chronic loop diuretics for heart failure present a particular challenge because stopping the drug may cause volume overload. In these cases, confirmatory testing (saline infusion test or fludrocortisone suppression test) after an elevated ARR is more practical than attempting a full washout [9].

Potassium-sparing diuretics (triamterene) raise aldosterone modestly through ENaC blockade. Four weeks off is recommended.

NSAIDs: A Frequently Overlooked Interference

Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, indomethacin, celecoxib) inhibit renal prostaglandin synthesis, which decreases renin release and reduces aldosterone production. The net effect on the ARR depends on the relative magnitude of suppression, but chronic NSAID use generally lowers both renin and aldosterone with a mild trend toward false positives [10].

The clinical reality is that patients rarely think to mention over-the-counter ibuprofen when asked about medications. Clinicians ordering ARR screening should specifically ask about NSAID use and recommend acetaminophen as an alternative for the two weeks preceding testing.

Indomethacin deserves special mention. It is sometimes used in confirmatory protocols (fludrocortisone-indomethacin suppression test) precisely because of its ability to suppress renin. In a diagnostic context, this effect is controlled. In an unplanned screening scenario, it introduces noise.

Oral Contraceptives and Estrogen Therapy

Combined oral contraceptives (ethinyl estradiol plus progestins) and estrogen-containing HRT affect the ARR through a specific mechanism. Estrogen increases hepatic synthesis of angiotensinogen, which drives up renin substrate and raises plasma renin activity. This lowers the ARR and can produce false-negative results.

A study of 85 women on combined OCPs found that mean plasma renin activity was 68% higher than in matched controls not taking hormonal contraception [8]. The guideline does not mandate OCP withdrawal before screening because stopping contraception creates its own clinical complications. Instead, the Endocrine Society recommends interpreting results with awareness that the ARR may be falsely low in women on estrogen-containing therapies [1].

Drospirenone-containing OCPs (Yaz, Yasmin) add a layer of complexity. Drospirenone is a spironolactone analog with antimineralocorticoid activity. It raises both renin and aldosterone. For women on drospirenone-containing OCPs who need PA screening, a four-week switch to a non-drospirenone formulation is the minimum requirement.

Safe Substitution Medications During Washout

The 2016 Endocrine Society guideline identifies four antihypertensive agents with minimal ARR interference [1]. These form the pharmacologic bridge during washout periods:

Verapamil sustained-release (120 to 240 mg daily) is the preferred first-line substitution. A study of 50 patients showed that verapamil SR changed the ARR by less than 5% compared to drug-free baseline [8]. It controls blood pressure through calcium channel blockade without affecting renin or aldosterone secretion pathways directly.

Hydralazine (25 to 50 mg three times daily) is a direct arteriolar vasodilator. It can cause reflex tachycardia and fluid retention, so it works best when paired with verapamil. It does not alter the ARR significantly.

Prazosin (1 to 5 mg two to three times daily) and doxazosin (1 to 8 mg daily) are alpha-1 blockers. They lower blood pressure through peripheral vasodilation. Alpha-1 blockers may slightly raise renin, but the magnitude is clinically insignificant for ARR interpretation [1].

Moxonidine and rilmenidine, imidazoline receptor agonists available outside the United States, also have minimal ARR effects and are used in European washout protocols [11].

Dr. John Funder, who chaired the original 2008 Endocrine Society guideline committee, has stated: "The biggest single barrier to diagnosing primary aldosteronism is not the disease. It is the failure to test for it properly, under the right medication conditions" [12].

Dietary and Physiological Factors That Also Affect Results

Drugs are not the only confounders. Sodium intake, posture, time of day, and potassium status all modify aldosterone levels.

A high-sodium diet (>200 mEq/day) suppresses aldosterone. A low-sodium diet (<50 mEq/day) stimulates it. The Endocrine Society recommends an unrestricted sodium diet before testing, with a concurrent 24-hour urine sodium to confirm intake [1]. A urine sodium below 100 mEq/day suggests dietary sodium restriction that could inflate aldosterone results.

Posture matters. Aldosterone rises 2- to 4-fold after two hours of upright posture compared to supine. Most screening protocols specify that blood should be drawn after the patient has been seated for 5 to 15 minutes, following at least two hours of being out of bed [1].

Severe dietary potassium restriction or chronic diarrhea causing hypokalemia will suppress aldosterone and can mask PA. Licorice consumption (real glycyrrhizin-containing licorice, not American-style candy) inhibits 11-beta-hydroxysteroid dehydrogenase type 2, mimicking mineralocorticoid excess without raising aldosterone.

The practical checklist before any ARR screen: confirm potassium is at least 4.0 mEq/L, verify sodium intake is unrestricted, confirm the patient has been upright for two hours, and review every medication including over-the-counter NSAIDs and supplements.

When You Cannot Complete a Full Washout

Some patients cannot safely stop their medications. A patient with heart failure on spironolactone and furosemide, or a patient with coronary disease on a beta-blocker, may face genuine risk from drug withdrawal. The guideline acknowledges this.

The practical approach is to screen anyway, interpret results directionally, and use confirmatory testing to resolve ambiguity [1]. If the ARR is above 30 with a plasma aldosterone concentration above 15 ng/dL while the patient remains on an ACE inhibitor, the result is highly suspicious for PA and should trigger CT imaging and adrenal vein sampling regardless of medication status [9].

Conversely, if the ARR is borderline (20 to 30) on a beta-blocker, the false-positive risk is high enough that repeating the test after a supervised taper is warranted before pursuing invasive workup.

A 2021 meta-analysis in the Journal of Clinical Endocrinology and Metabolism evaluated 14 studies and found that screening on interfering medications had 78% sensitivity and 72% specificity for PA, compared to 89% and 91% when medications were properly withdrawn [13]. The accuracy gap is real but not absolute. Testing imperfectly is better than not testing at all for high-risk patients.